News from bioarctic A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

18 Nov, 2019, 23:19 GMT BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with...


18 Jul, 2019, 06:15 BST BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by...


15 Jul, 2019, 16:17 BST BioArctic's Co-Founder Received AAIC Lifetime Achievement Award

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University ...


11 Jul, 2019, 06:40 BST BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer's Association...


23 May, 2019, 07:14 BST BioArctic Strengthens its Blood-brain Barrier Technology Platform With World Leading Scientist Recruitment

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. Per-Ola...


20 May, 2019, 17:01 BST BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai...


10 May, 2019, 08:54 BST BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer's Clinical Trials Consortium (ACTC) and BioArctic's partner Eisai...


03 Apr, 2019, 14:57 BST BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 from Sweden's Innovation...


22 Mar, 2019, 00:01 GMT BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401...


13 Mar, 2019, 23:28 GMT BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is...


07 Mar, 2019, 08:35 GMT BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with...


14 Feb, 2019, 07:23 GMT BioArctic - Full Year Report January - December 2018

BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson portfolio...


13 Feb, 2019, 07:58 GMT BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated ...


11 Feb, 2019, 16:16 GMT BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of...


04 Feb, 2019, 09:12 GMT BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019...


14 Dec, 2018, 07:23 GMT BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade...


12 Nov, 2018, 07:20 GMT BioArctic is Awarded Grant From EU's Horizon 2020 for Participation in Research Consortium for Better Diagnostic Tools and Biomarkers for Parkinson's

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been awarded a grant from EU's research and innovation program Horizon 2020. The grant (Grant...


08 Nov, 2018, 07:40 GMT Interim Report January - September 2018

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson's projects July –...


02 Nov, 2018, 03:13 GMT BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research,...


25 Oct, 2018, 13:47 BST BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical Phase 2b study...


21 Oct, 2018, 13:59 BST BioArctic is Granted a Concept Patent in Europe for the Company's Strategy for Disease-modifying Treatment of Parkinson's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) announced today that the European Patent Office (EPO) has issued a decision to grant the company's...


03 Oct, 2018, 13:45 BST BioArctic Receives European Patent Protection for a Medical Device for Treatment of Patients with Complete Spinal Cord Injury

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant the company's...


13 Sep, 2018, 11:18 BST BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). BBS was founded ...


03 Sep, 2018, 13:58 BST BioArctic Expands the Research Collaboration With Uppsala University Concerning Antibody-based Diagnostic Imaging of the Brain in Alzheimer Patients

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that the company has signed an expanded research collaboration agreement with Uppsala...


07 Aug, 2018, 19:09 BST BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides an...